This will fail. It’s more like a steroid instead of the unique ingredients of Acthar. No need to worry they now have to do phase 1, 2 and 3 clinical trials which will take forever. We are fine.
The post said they are in phase 3. I checked their website and it says phase 3. It's a different drug than Acthar and it isn't a bio so I can't be a similar. They may be under an SPA with the FDA for a boiler plate label like Acthar. If so, lights out.This will fail. It’s more like a steroid instead of the unique ingredients of Acthar. No need to worry they now have to do phase 1, 2 and 3 clinical trials which will take forever. We are fine.
The post said they are in phase 3. I checked their website and it says phase 3. It's a different drug than Acthar and it isn't a bio so I can't be a similar. They may be under an SPA with the FDA for a boiler plate label like Acthar. If so, lights out.
you must have some concern, or you wouldn't have so much knowledge about the earnings call.
This will fail. It’s more like a steroid instead of the unique ingredients of Acthar. No need to worry they now have to do phase 1, 2 and 3 clinical trials which will take forever. We are fine.
“UNIQUE INGREDIENTS OF ACTHAR” - nothing unique about pig hormone. Just eat bacon! The only thing “unique” about it is that ingredients are not disclosed. Say.......you take it since you and acthar are so “unique”! What a dog face you are! Dummy.
Remember this fool. They just filed an NDA. The payers will allow and pay for it to be used off label. The price of Acthar will have to match it or Acthar will die a sudden death. The commercial organization will be brought down to bare bones, the debt load from Acthar won't be able to be paid, the company will file for bankruptcy and be liquidated.DEPOMED again. HAHAHAHAA!!!! Tell them to pony up $1B for trials.
In the third quarter, the Company completed its reincorporation from California to Delaware and changed its name from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” In connection with the reincorporation and name change, the Company’s common stock began trading under a new ticker symbol “ASRT” and a new CUSIP number, 04545L 107, on August 15, 2018.
Remember this fool. They just filed an NDA. The payers will allow and pay for it to be used off label. The price of Acthar will have to match it or Acthar will die a sudden death. The commercial organization will be brought down to bare bones, the debt load from Acthar won't be able to be paid, the company will file for bankruptcy and be liquidated.
Not true . They will have to do phase 1. 2 and 3 clinical trials and we don’t have to at all. Acthar isn’t going any where.
It depends on debt service. Instead of paying down debt, the fools bought products that failed. The price of Acthar has been raised to cover declining sales to pay debt. With a new ACTH, not only will sales volume decline, but the price will be forced down.can the company survive without Acthar sales? Looks like Acthar won’t be around much longer.
